Yue Lilly Q, Lu Nelson, Xu Yunling
a Center for Devices and Radiological Health, U.S. Food and Drug Administration , Silver Spring , Maryland , USA.
J Biopharm Stat. 2014;24(5):994-1010. doi: 10.1080/10543406.2014.926367.
Due to the special nature of medical device clinical studies, observational (nonrandomized) comparative studies play important roles in the premarket safety/effectiveness evaluation of medical devices. While historical data collected in earlier investigational device exemption studies of a previously approved medical device have been used to form control groups in comparative studies, high-quality registry data are emerging to provide opportunities for the premarket evaluation of new devices. However, in such studies, various biases could be introduced in every stage and aspect of study and may compromise the objectivity of study design and validity of study results. In this article, challenges and opportunities in the design of such studies using propensity score methodology are discussed from regulatory perspectives.
由于医疗器械临床研究的特殊性,观察性(非随机)对比研究在医疗器械上市前安全性/有效性评估中发挥着重要作用。虽然在先前批准的医疗器械早期研究性器械豁免研究中收集的历史数据已被用于在对比研究中形成对照组,但高质量的注册数据正在涌现,为新器械的上市前评估提供了机会。然而,在这类研究中,研究的各个阶段和方面都可能引入各种偏差,这可能会损害研究设计的客观性和研究结果的有效性。本文从监管角度讨论了使用倾向评分方法进行这类研究设计时面临的挑战和机遇。